Lifesaving drug now available for kids with rare gut disease
NCT ID NCT06003881
First seen Nov 11, 2025 · Last updated May 23, 2026 · Updated 25 times
Summary
This program provides access to an experimental drug called pozelimab for people with CHAPLE disease, a rare and life-threatening immune disorder that causes protein loss from the gut. The goal is to offer treatment and track long-term safety. Participants must have a confirmed genetic diagnosis of CD55-deficient protein-losing enteropathy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD55-DEFICIENT PROTEIN-LOSING ENTEROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.